May be taken with or without food. Should be taken w/ a full glass of water (240 mL) w/ each dose of medication & at frequent intervals throughout the day.
Administration
May be taken with or without food. Should be taken w/ a full glass of water (240 mL) w/ each dose of medication & at frequent intervals throughout the day.
|
Contraindications
Hypersensitivity to sulfonamides. Acute porphyria, blood disorders, jaundice. Severe renal or hepatic impairment. Infants <2 mth (except in the treatment of toxoplasmosis). Pregnancy and lactation. Concomitant use w/ clozapine.
|
Special Precautions
Patient w/ G6PD deficiency, history of allergy or asthma, AIDS, lupus erythematosus, predisposition to folate deficiency. Mild to moderate hepatic and renal impairment. Childn. Patient Counselling Maintain adequate fluid intake. Monitoring Parameters Perform culture and sensitivity test prior to initiation of therapy. Monitor CBC and urinalysis (during therapy), CD4+ count in HIV-exposed/+ve patients treated for toxoplasmosis.
|
Adverse Reactions
Significant: Bacterial or fungal superinfection (prolonged use).
Nervous: Headache, convulsions, hallucinations, mental depression, ataxia, insomnia, vertigo, peripheral neuritis.
GI: Diarrhoea, nausea, vomiting, anorexia, abdominal pain, pancreatitis, stomatitis.
Hepatic: Hepatitis, neonatal jaundice and kernicterus.
Genitourinary: Crystalluria, anuria, oliguria.
Haematologic: Eosinophilia, leucopenia, thrombocytopenia.
Otic: Tinnitus.
Dermatologic: Rash, skin reactions.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis; blood dyscrasias (e.g. agranulocytosis, aplastic anaemia), hepatic necrosis. |
C
D if administered near term.
|
Drug Interactions
May enhance the hypoglycaemic effect of sulfonylureas. Action antagonised by PABA and procaine group of local anaesthetics. May potentiate the effects of oral anticoagulants (e.g. warfarin), methotrexate, phenytoin, thiopentone anaesthetics. May decrease serum levels of ciclosporin. Increased risk of toxicity w/ aspirin. Increased risk of crystalluria w/ diuretics. May reduce the effect of oestrogen-containing OCs.
|
CIMS Class
|
ATC Classification
J01EC02 - sulfadiazine ; Belongs to the class of intermediate-acting sulfonamides. Used in the systemic treatment of infections.
|